Remove Antibody Remove Gene Editing Remove Protein
article thumbnail

Leading innovators in CRISPR nucleases for the pharmaceutical industry

Pharmaceutical Technology

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 162
article thumbnail

How Researchers Stumbled Upon an Arthritis Vaccine Just in Time for World Arthritis Day

XTalks

14-3-3 zeta) protein, which the UToledo researchers had been studying for its role in immune-related pathologies, such as aortic aneurysms and in signaling pathways involving the pro-inflammatory cytokine interleukin-17. However, they found the opposite to be true, where the protein was actually protective against development of the disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nedisertib by Merck for Neuroendocrine Tumors: Likelihood of Approval

Pharmaceutical Technology

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The drug candidate is administered through the oral route in the form of capsule and tablet.

article thumbnail

Nedisertib by Merck for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approval

Pharmaceutical Technology

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The drug candidate is administered through the oral route in the form of capsule and tablet.

article thumbnail

Using bispecific antibodies to advance cancer immunotherapy

pharmaphorum

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

article thumbnail

Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal

pharmaphorum

The Danish drugmaker is paying $100 million upfront for rights to antibody drug PRX004, which is heading for phase 2 trials in cardiomyopathy associated with ATTR amyloidosis, a life-threatening disease affecting the heart and nervous system. The post Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal appeared first on.

article thumbnail

Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies

Worldwide Clinical Trials

Tofersen (Intrathecal injection) This is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. Additional research is underway using gene editing via CRISPR, primarily investigating genes with known relationships to ALS, such as SOD1 and C9orf72.

Gene 204